These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 12023785)
1. Pemetrexed, an novel multitargeted antifolate: current development and future directions. Proceedings of a meeting. August 17-19, 2000. Colorado Springs, Colorado, USA. Semin Oncol; 2002 Apr; 29(2 Suppl 5):1-61; quiz 62-9. PubMed ID: 12023785 [No Abstract] [Full Text] [Related]
2. MTA, A Novel Multitargeted Antifolate: from preclinical to phase I and beyond. Proceedings of a meeting. Ixtapa, Mexico, March 13-15, 1998. Semin Oncol; 1999 Apr; 26(2 Suppl 6):1-110. PubMed ID: 10610578 [No Abstract] [Full Text] [Related]
3. MTA, a novel multitargeted antifolate, from preclinical to phase I and beyond: summary and conclusions. Calvert H Semin Oncol; 1999 Apr; 26(2 Suppl 6):105-8. PubMed ID: 10598564 [No Abstract] [Full Text] [Related]
4. Pemetrexed: a multitargeted antifolate (ALIMTA, LY-231514). Jones RJ; Twelves CJ Expert Rev Anticancer Ther; 2002 Feb; 2(1):13-22. PubMed ID: 12113062 [TBL] [Abstract][Full Text] [Related]
5. Preclinical development of Alimta (Pemetrexed, LY231514), a multitargeted antifolate. Schultz RM Prog Drug Res; 2005; 63():275-300. PubMed ID: 16265884 [No Abstract] [Full Text] [Related]
7. Pemetrexed in bladder, head and neck, and cervical cancers. Paz-Ares L; Ciruelos E; García-Carbonero R; Castellano D; Lopez-Martín A; Cortés-Funes H Semin Oncol; 2002 Dec; 29(6 Suppl 18):69-75. PubMed ID: 12571815 [TBL] [Abstract][Full Text] [Related]
8. The role of pemetrexed in the treatment of colorectal cancer. Hochster H Semin Oncol; 2002 Dec; 29(6 Suppl 18):54-6. PubMed ID: 12571812 [TBL] [Abstract][Full Text] [Related]
10. Antifolates: the next millennium. Allegra CJ Semin Oncol; 1999 Apr; 26(2 Suppl 6):1-2. PubMed ID: 10598548 [No Abstract] [Full Text] [Related]
11. The emerging role of pemetrexed (Alimta) and gemcitabine in non-small cell lung cancer. Le Chevalier T Semin Oncol; 2003 Aug; 30(4 Suppl 10):37-44. PubMed ID: 12947960 [TBL] [Abstract][Full Text] [Related]
12. An overview of folate metabolism: features relevant to the action and toxicities of antifolate anticancer agents. Calvert H Semin Oncol; 1999 Apr; 26(2 Suppl 6):3-10. PubMed ID: 10598549 [No Abstract] [Full Text] [Related]
13. Overview of phase I trials of multitargeted antifolate (MTA, LY231514). Rinaldi DA Semin Oncol; 1999 Apr; 26(2 Suppl 6):82-8. PubMed ID: 10598560 [TBL] [Abstract][Full Text] [Related]
14. Clinical activity of pemetrexed: a multitargeted antifolate anticancer agent. Solomon B; Bunn PA Future Oncol; 2005 Dec; 1(6):733-46. PubMed ID: 16556051 [TBL] [Abstract][Full Text] [Related]
16. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Hanauske AR; Chen V; Paoletti P; Niyikiza C Oncologist; 2001; 6(4):363-73. PubMed ID: 11524555 [TBL] [Abstract][Full Text] [Related]
17. Enter Alimta: a new generation antifolate. Zhao R; Goldman ID Oncologist; 2004; 9(3):242-4. PubMed ID: 15169978 [No Abstract] [Full Text] [Related]
18. Future directions in the development of pemetrexed. Calvert H; Bunn PA Semin Oncol; 2002 Apr; 29(2 Suppl 5):54-61. PubMed ID: 12023794 [TBL] [Abstract][Full Text] [Related]
19. Pemetrexed: an active new agent for breast cancer. O'Shaughnessy JA Semin Oncol; 2002 Dec; 29(6 Suppl 18):57-62. PubMed ID: 12571813 [TBL] [Abstract][Full Text] [Related]